103
views
0
recommends
+1 Recommend
0 collections
    1
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis.

          Related collections

          Author and article information

          Journal
          N Engl J Med
          The New England journal of medicine
          Massachusetts Medical Society
          1533-4406
          0028-4793
          Mar 01 2012
          : 366
          : 9
          Affiliations
          [1 ] Leukemia Department, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. sverstov@mdanderson.org
          Article
          NIHMS772841
          10.1056/NEJMoa1110557
          4822164
          22375971
          828f5201-2331-469f-a5b3-b1ee357b85a0
          History

          Comments

          Comment on this article